Form 4: Lava Therapeutics Director Acquires Options in Recent Transaction
SEC Form 4
Director James Noble acquired options to purchase 33,390 common shares of Lava Therapeutics at $0.93 per share.
Summary
- On February 13, 2025, James Noble, a director of LAVA Therapeutics N.V., acquired options to purchase 33,390 common shares.
- The exercise price of the options is $0.93 per share.
- The options vest on February 13, 2026, contingent upon continued service with the Issuer or its subsidiary.
- The options expire on February 12, 2035.
- Following the transaction, Mr. Noble directly owns 33,390 common shares.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock options, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The transaction could have a minor impact on shareholders by potentially diluting the stock if the options are exercised in the future.
Key Dates
| Date | Description |
|---|---|
| 02/13/2025 | Date of transaction: Director James Noble acquired options to purchase common shares. |
| 02/13/2026 | Vesting date: 100% of the shares underlying the option will vest, provided the Reporting Person remains in a service relationship with the Issuer. |
| 02/12/2035 | Expiration date: Options expire on this date. |
| 02/18/2025 | Date of report. |
Keywords
LAVA Therapeutics, Director, Options, Acquisition, Common Shares, Beneficial Ownership, Form 4, LVTX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.